Arsenic trioxide is a potent inhibitor of the interaction of SMRT corepressor with its transcription factor partners, including the PML-retinoic acid receptor α oncoprotein found in human acute promyelocytic leukemia

Molecular and Cellular Biology

Volumn 21, Issue 21, 2001, Pages 7172-7182

  Hong, S H ^a   Yang, Z ^a   Privalsky, M L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CELL PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; ONCOPROTEIN; PROTEIN SMRT; RETINOIC ACID RECEPTOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; CANCER REGRESSION; CARCINOGENESIS; CELLULAR DISTRIBUTION; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME MECHANISM; HUMAN; HUMAN CELL; ONCOGENE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; TRANSCRIPTION REGULATION; VERTEBRATE;

ANIMALS; ANTINEOPLASTIC AGENTS; ARSENICALS; CELL DIFFERENTIATION; CELL NUCLEUS; DNA-BINDING PROTEINS; ENZYME ACTIVATION; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MAP KINASE SIGNALING SYSTEM; MICROSCOPY, CONFOCAL; OXIDES; PHOSPHORYLATION; PLASMIDS; PRECIPITIN TESTS; PROTEIN BINDING; RECEPTORS, RETINOIC ACID; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; TWO-HYBRID SYSTEM TECHNIQUES;

VERTEBRATA;

EID: 0034786069     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.21.21.7172-7182.2001     Document Type: Article

References (70)

1. Histone deacetylases: Transcriptional repression with SINers and NuRDs
2. The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase
3. A decade of molecular biology of retinoic acid receptors
4. 3 exerts dose-dependent dual effects on APL cells
5. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins
6. A transcriptional co-repressor that interacts with nuclear hormone receptors
7. Coactivation and corepression in transcriptional regulation by steroid/nuclear hormone receptors
8. Acute promyelocytic leukemia: From clinic to molecular biology
9. Tumor promoter arsenite activates extracellular signal-regulated kinase through a signaling pathway mediated by epidermal growth factor receptor and Shc
10. Nuclear receptors: Coactivators, corepressors and chromatin remodeling in the control of transcription
11. Altered retinoic acid receptors
12. Two receptor interaction domains in the corepressor, N-CoR/RIP13, are required for an efficient interaction with Rev-erbA alpha and RVR: Physical association is dependent on the E region of the orphan receptors
13. Identification of a nuclear domain with deacetylase activity
14. Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells
15. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia
16. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARcα underlie molecular pathogenesis and treatment of acute promyelocytic leukemia
17. Distinct interactions of PML-RARα and PLZF-RARα with co-repressors determine differential responses to RA in APL
18. SMRT corepressor interacts with PLZF and with the PML-retinoic acid receptor alpha (RARα) and PLZF-RARα oncoproteins associated with acute promyelocytic leukemia
19. Signaling by tyrosine kinases negatively regulates the interaction between transcription factors and SMRT (silencing mediator of retinoic acid and thyroid hormone receptor) corepressor
20. SMRT corepressor is regulated by a MEK-1 kinase pathway: Inhibition of corepressor function is associated with SMRT phosphorylation and nuclear export
21. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor
22. Nuclear receptor coactivators and corepressors
23. The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors
24. Nuclear receptor corepressors partner with class II histone deacetylases in a Sin3-independent repression pathway
25. Identity between TRAP and SMCC complexes indicates novel pathways for the function of nuclear receptors and diverse mammalian activators
26. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway
27. Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression
28. 3+) and other metal ions on acute promyelocytic leukemia cells
29. The t(15;17) translocation in acute promyelocytic leukemia
30. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes
31. Characterization of receptor interaction and transcriptional repression by the corepressor SMRT
32. Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3
33. A conformational switch in nuclear hormone receptors is involved in coupling hormone binding to corepressor release
34. Acquisition of oncogenic potential by PAR chimeras in acute promyelocytic leukemia through formation of homodimers
35. Role of the histone deacetylase complex in acute promyelocytic leukaemia
36. Differential activation of ERK, JNK/SAPK and P38/CSBP/RK map kinase family members during the cellular response to arsenite
37. The stress inducer arsenite activates mitogen-activated protein kinases extracellular signal-regulated kinases 1 and 2 via a MAPK kinase 6/p38-dependent pathway
38. The nuclear receptor superfamily: The second decade
39. Regulation of gene expression by nuclear hormone receptors
40. Cellular stresses and cytokines activate multiple mitogen-activated-protein kinase kinase homologues in PC12 and KB cells
41. The APL-associated fusion proteins
42. Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation
43. Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus
44. Mechanism of corepressor binding and release from nuclear hormone receptors
45. PML, PLZF and NPM genes in the molecular pathogenesis of acute promyelocytic leukemia
46. What's up and down with histone deacetylation and transcription?
47. Molecular determinants of nuclear receptor-corepressor interaction
48. Signal transduction pathways regulated by arsenate and arsenite
49. Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex
50. Identification of TRACs (T3 receptor-associating cofactors), a family of cofactors that associate with, and modulate the activity of, nuclear hormone receptors
51. Two receptor interacting domains in the nuclear hormone receptor corepressor RIP13/N-CoR
52. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells
53. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients
54. Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action
55. Mechanisms of arsenic carcinogenicity: Genetic or epigenetic mechanisms?
56. Biology and treatment of acute progranulocytic leukemia
57. Differential effects of nuclear receptor corepressor (N-CoR) expression levels on retinoic acid receptor-mediated repression support the existence of dynamically regulated corepressor complexes
58. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide
59. P1C-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia
60. Co-activators and corepressors in the integration of transcriptional responses
61. Molecular mechanisms of action of steroid/thyroid receptor superfamily members
62. The nuclear corepressors NCoR and SMRT are key regulators of both ligand- and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor
63. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARα independent manner
64. Transcriptional silencing is defined by isoform- and heterodimer-specific interactions between nuclear hormone receptors and corepressors
65. Alteration of nucleosome structure as a mechanism of transcriptional regulation
66. Coactivator and corepressor complexes in nuclear receptor function
67. A nuclear hormone receptor corepressor mediates transcriptional silencing by receptors with distinct repression domains
68. 3) in the treatment of acute promyelocytic leukemia
69. Arsenic-induced PML targeting onto nuclear bodies: Implications for the treatment of acute promyelocytic leukemia
70. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations